Neutralization of recombinant RBD-subunit vaccine ZF2001-elicited antisera to SARS-CoV-2 variants including Delta
Preprint
- 16 July 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
SARS-CoV-2 variants brought new waves of infection worldwide. In particular, Delta variant (B.1.617.2 lineage) has become predominant in many countries. These variants raised the concern for their potential immune escape to the currently approved vaccines. ZF2001 is a subunit vaccine received emergency use authorization (EUA) in both China and Uzbekistan, with more than 100-million doses administrated with a three-dose regimen. The tandem-repeat dimer of SARS-CoV-2 spike protein receptor binding domain (RBD) was used as the antigen. In this work, we evaluated the neutralization of ZF2001-elicited antisera to SARS-CoV-2 variants including all four variants of concern (Alpha, Beta, Gamma and Delta) and other three variants of interest (Epsilon, Eta and Kappa) by pseudovirus-based assay. We found antisera preserved majority of the neutralizing activity against these variants. E484K/Q substitution is the key mutation to reduce the RBD-elicited sera neutralization. Moreover, ZF2001-elicited sera with a prolonged intervals between the second and third dose enhanced the neutralizing titers and resilience to SARS-CoV-2 variants.Keywords
This publication has 18 references indexed in Scilit:
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature, 2021
- SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthroughPublished by Research Square Platform LLC ,2021
- Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021Eurosurveillance, 2021
- SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectivenessThe Lancet, 2021
- BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variantsNature, 2021
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccinationThe Lancet, 2021
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesCell, 2021
- Transmission Dynamics of an Outbreak of the COVID-19 Delta Variant B.1.617.2 — Guangdong Province, China, May–June 2021China CDC Weekly, 2021
- New at Cell Press: The Inclusion and Diversity StatementCell, 2021
- A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARSCell, 2020